Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Recruiting

SMOFlipidSafety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Sponsor:

Fresenius Kabi

Code:

NCT06049680

Conditions

Malnutrition, Child

Malnutrition

Essential Fatty Acid Deficiency (EFAD)

Parenteral Nutrition Associated Cholestasis

Eligibility Criteria

Sex: All

Age: 1 - 17

Healthy Volunteers: Not accepted

Interventions

SMOFlipid® (lipid injectable emulsion)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Fresenius Kabi on 2025-04-16.